

---

**From:** Love, Jane M. [mailto:JLove@gibsondunn.com]  
**Sent:** Tuesday, September 05, 2017 10:35 AM  
**To:** Trials <Trials@USPTO.GOV>  
**Cc:** Love, Jane M. <JLove@gibsondunn.com>; Trenchard, Robert W. <RTrenchard@gibsondunn.com>; 'ahollis@kirkland.com' <ahollis@kirkland.com>  
**Subject:** IPR2017-01946 – Petitioner’s Joinder Motion to Join IPR2017-00854

To the Patent Trial and Appeal Board:

I represent Patent Owner Novartis in the above IPRs. I write to inform the Board that Novartis does not object to Petitioner Teva’s and its affiliates’ Motion for Joinder of IPR2017-01946 with now-instituted IPR2017-00854, as the Petition in IPR2017-01946 is substantively the same as the Petition in IPR2017-00854, and Petitioners has agreed not to pursue any arguments or make any filings separate from those made by the Petitioner in IPR2017-00854, subject to reserving Petitioners’ right to take a lead role in the event Apotex drops out of IPR2017-00854. I accordingly respectfully request that the Board grant Teva’s and its affiliates’ joinder motion, and Novartis hereby agrees not to submit a Preliminary Response to Teva’s Petition.

Respectfully submitted,  
Jane M. Love, Ph.D. (Reg. No. 42,812)  
Lead Counsel for Patent Owner  
**Jane M. Love, Ph.D.**

## GIBSON DUNN

Gibson, Dunn & Crutcher LLP  
200 Park Avenue, New York, NY 10166-0193  
Tel +1 212.351.3922 • Fax +1 212.351.6322  
JLove@gibsondunn.com • www.gibsondunn.com

---

This message may contain confidential and privileged information. If it has been sent to you in error, please reply to advise the sender of the error and then immediately delete this message.